Odontoprev (ODPV3) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
11 May, 2026Executive summary
Achieved revenues of R$13.4 billion in 1Q26, with net income of R$1.3 billion and a total of 13.4 million members, reflecting strong growth and scale in the healthcare ecosystem.
Celebrated the launch of the SAUD3 ticker and entry into B3, marking a new phase for the company.
Major corporate restructuring completed, merging Bradesco Saúde, Odontoprev, and other assets under Bradsaúde.
The ecosystem integrates health and dental insurance, hospitals, clinics, diagnostics, and technology, serving over 13 million beneficiaries nationwide.
Highlighted 20 years of value generation since IPO, with significant growth in revenues and market value.
Financial highlights
Revenues reached R$13.4 billion in 1Q26, with written premiums of R$13.3 billion, up 8.4% year-over-year.
Net income for 1Q26 was R$1.3 billion, with Bradesco Saúde contributing 83%, Odontoprev 11%, Atlântica Hospitais 5%, and others 1%.
Financial assets totaled R$28.6 billion at the end of 1Q26, with financial results of R$875 million.
Odontoprev net revenue grew at a 15% CAGR since IPO, reaching R$2.4 billion in MAR26.
No debt, maintaining a robust capital structure.
Outlook and guidance
Management expressed caution regarding claims ratio trends for 2026, citing seasonality and rising medical inflation.
Focus remains on sustainable growth, balancing member expansion with margin protection and price discipline.
Ongoing investment in technology, digital health, and analytics to manage claims and operational efficiency.
Continued expansion of hospital network with new openings scheduled through 2029, including Santa Lúcia Gama and Albert Einstein Vila Mariana.
The group emphasizes innovation, operational excellence, and long-term sustainability.
Latest events from Odontoprev
- Membership and revenue growth fueled margin expansion and strong cash generation in 2025.ODPV3
Q4 20258 Apr 2026 - Record net income, margin expansion, and SME/Individual growth with strong cash position.ODPV3
Q3 20243 Feb 2026 - Record profitability, margin expansion, and 100% net income payout in 2Q24.ODPV3
Q2 20242 Feb 2026 - High-margin, tech-focused dental insurer grows SME segment, sustains top dividends, and zero debt.ODPV3
Status update28 Jan 2026 - Record recurring net income, margin expansion, and high payouts marked a strong 2024.ODPV3
Q4 20246 Jan 2026 - Record SME and Individual plan growth, margin expansion, and strong cash generation.ODPV3
Q2 202523 Nov 2025 - EBITDA margin rose to 38.3% in Q1 2025, led by SME and individual segment growth.ODPV3
Q1 202519 Nov 2025 - Record SME and Individual plan growth drove revenue, margin, and shareholder return gains.ODPV3
Q3 202513 Nov 2025